Online Only Articles

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Quantitative Health Sciences, Cleveland Clinic, OH, USA
Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, NY, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
Department of Quantitative Health Sciences, Cleveland Clinic, OH, USA
Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, NY, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA
Vol. 101 No. 6 (2016): June, 2016 https://doi.org/10.3324/haematol.2015.140962